Clinical trial
A Phase 2 Multicenter, Randomized, Double-Masked, Sham-Controlled Study of the Safety and Efficacy of Intravitreal Injections of NGM621 in Subjects With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
NCT04465955 is registered in ClinicalTrials.gov with NGM Biopharmaceuticals, Inc as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Multicenter, Randomized, Double-Masked, Sham-Controlled Study of the Safety and Efficacy of Intravitreal Injections of NGM621 in Subjects With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
- Lead sponsor
- NGM Biopharmaceuticals, Inc
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- July 22, 2020
- Completion date
- August 16, 2022
- Enrollment
- 320 (actual)
- Sites
- 65
Conditions
As the registry lists them; a condition with its own page is linked.